\u010cesk\u00fd MedTech p\u0159est\u00e1v\u00e1 b\u00fdt okrajov\u00fdm t\u00e9matem a za\u010d\u00edn\u00e1 se profilovat jako sektor, kter\u00fd um\u00ed spojit technologickou inovaci, klinickou vyu\u017eitelnost a zaj\u00edmav\u00fd r\u016fst hodnoty. Pr\u00e1v\u011b v tomto prost\u0159ed\u00ed se st\u00e1le v\u00fdrazn\u011bji profiluje tak\u00e9 H2 Global Group, skupina zam\u011b\u0159en\u00e1 na v\u00fdvoj, klinickou validaci a investi\u010dn\u00ed rozvoj zdravotnick\u00fdch technologi\u00ed s mezin\u00e1rodn\u00edm potenci\u00e1lem. Jedn\u00edm z konkr\u00e9tn\u00edch d\u016fkaz\u016f, \u017ee tento p\u0159\u00edstup velmi dob\u0159e funguje, je p\u0159\u00edb\u011bh spole\u010dnosti VR LIFE a jej\u00edho produktu VR Vitalis.<\/p>\n\n\n\n
V \u010dervnu 2023 vstoupila do VR LIFE dce\u0159in\u00e1 spole\u010dnost H2 Investment ze skupiny H2 Global Group investic\u00ed ve v\u00fd\u0161i 15 milion\u016f korun v\u00fdm\u011bnou za 20% pod\u00edl. U\u017e tehdy \u0161lo o vstup do projektu, kter\u00fd m\u011bl za sebou siln\u00fd technologick\u00fd z\u00e1klad, klinickou vyu\u017eitelnost i ambici \u0161k\u00e1lovat \u0159e\u0161en\u00ed za hranice dom\u00e1c\u00edho trhu. Pr\u00e1v\u011b tento krok dnes ukazuje, \u017ee dob\u0159e na\u010dasovan\u00e1 investice do medic\u00ednsk\u00e9 technologie m\u016f\u017ee vytvo\u0159it v\u00fdraznou hodnotu je\u0161t\u011b p\u0159ed p\u0159\u00edpadn\u00fdm strategick\u00fdm prodejem.<\/p>\n\n\n\n
Dal\u0161\u00ed valida\u010dn\u00ed moment p\u0159i\u0161el v \u00fanoru 2026, kdy VR LIFE uzav\u0159ela \u201eseed\u201c investi\u010dn\u00ed kolo ve v\u00fd\u0161i 600 tis\u00edc eur, do n\u011bho\u017e vstoupili mimo jin\u00e9 Garage Angels a Electron CP. Podle materi\u00e1l\u016f H2 Global Group se po tomto kole pod\u00edl H2 Investment na\u0159edil na 18,26 %, av\u0161ak implikovan\u00e1 hodnota tohoto pod\u00edlu vzrostla na p\u0159ibli\u017en\u011b 1,278 milionu eur, tedy zhruba 31,2 milionu korun. To p\u0159edstavuje v\u00edce ne\u017e dvojn\u00e1sobek p\u016fvodn\u00ed investice. Nejde sice o realizovan\u00fd v\u00fdnos, ale o jasn\u00fd sign\u00e1l, \u017ee spr\u00e1vn\u011b vybran\u00fd \u010desk\u00fd MedTech projekt m\u016f\u017ee b\u00fdt ji\u017e v dal\u0161\u00edm investi\u010dn\u00edm kole rychle p\u0159ecen\u011bn vy\u0161\u0161\u00ed valuac\u00ed.<\/p>\n\n\n\n
S\u00edla tohoto p\u0159\u00edb\u011bhu p\u0159itom nestoj\u00ed jen na investi\u010dn\u00edch \u010d\u00edslech, ale p\u0159edev\u0161\u00edm na tom, \u017ee VR LIFE vybudovala produkt s re\u00e1ln\u00fdm vyu\u017eit\u00edm ve zdravotnictv\u00ed. VR Vitalis Pro je certifikovan\u00fd zdravotnick\u00fd prost\u0159edek ur\u010den\u00fd pro rehabilitaci pacient\u016f ve zdravotnick\u00fdch za\u0159\u00edzen\u00edch. VR LIFE spolupracuje nap\u0159\u00edklad s FN Ostrava, Rehabilita\u010dn\u00edm \u00fastavem Hrabyn\u011b, Nemocnic\u00ed AGEL Ostrava-V\u00edtkovice, L\u00e1zn\u011bmi Darkov, Rehabilita\u010dn\u00ed nemocnic\u00ed Beroun, Malvazinkami, FNO Olomouc, Centrem pohybov\u00e9 medic\u00edny Pavla Kol\u00e1\u0159e nebo l\u00e1ze\u0148sk\u00fdmi skupinami Royal Spa a Priessnitzovy l\u00e9\u010debn\u00e9 l\u00e1zn\u011b Jesen\u00edk. Podle spole\u010dnosti je produkt nasazen ji\u017e ve v\u00edce ne\u017e 40 zdravotnick\u00fdch za\u0159\u00edzen\u00edch a soukrom\u00fdch ambulanc\u00edch.<\/p>\n\n\n\n
V\u00fdznamn\u00fdm momentem bylo tak\u00e9 z\u00edsk\u00e1n\u00ed ocen\u011bn\u00ed Firma roku 2024 v Moravskoslezsk\u00e9m kraji. Spole\u010dnost sou\u010dasn\u011b rozv\u00edj\u00ed registra\u010dn\u00ed aktivity u americk\u00e9ho \u00da\u0159adu pro kontrolu potravin a l\u00e9\u010div (FDA) s c\u00edlem vstoupit na trh v USA v pr\u016fb\u011bhu n\u011bkolika n\u00e1sleduj\u00edc\u00edch m\u011bs\u00edc\u016f. Pr\u00e1v\u011b kombinace klinick\u00e9 vyu\u017eitelnosti, regulatorn\u00ed p\u0159ipravenosti a zahrani\u010dn\u00ed expanze je jedn\u00edm z d\u016fvod\u016f, pro\u010d se podobn\u00e9 projekty st\u00e1vaj\u00ed investi\u010dn\u011b st\u00e1le atraktivn\u011bj\u0161\u00edmi.<\/p>\n\n\n\n
\u201eJi\u017e n\u011bkolik let sn\u00edm o tom, \u017ee budeme moci pom\u00e1hat lidem po cel\u00e9m sv\u011bt\u011b a sou\u010dasn\u011b vybudovat siln\u00fd a funk\u010dn\u00ed obchodn\u00ed model, kter\u00fd potvrd\u00ed \u017eivotaschopnost cel\u00e9ho syst\u00e9mu. D\u00edky VR Vitalis a na\u0161emu unik\u00e1tn\u00edmu \u0159e\u0161en\u00ed, se kter\u00fdm expandujeme do zahrani\u010d\u00ed, se tento sen za\u010d\u00edn\u00e1 postupn\u011b napl\u0148ovat,\u201c \u0159\u00edk\u00e1 Jana Trd\u00e1, Ph.D., zakladatelka VR LIFE.<\/p>\n\n\n\n
Pr\u00e1v\u011b oblast rehabilitace a neurorehabilitace pat\u0159\u00ed mezi segmenty, kde digit\u00e1ln\u00ed zdravotnick\u00e9 technologie d\u00e1vaj\u00ed mimo\u0159\u00e1dn\u00fd smysl. V dob\u011b rostouc\u00ed popt\u00e1vky po p\u00e9\u010di a nedostatku person\u00e1lu se \u0159e\u0161en\u00ed, kter\u00e1 zvy\u0161uj\u00ed efektivitu p\u00e9\u010de, motivaci pacient\u016f a kapacitu rehabilitace, st\u00e1vaj\u00ed struktur\u00e1ln\u00ed pot\u0159ebou. I proto je dnes MedTech pro investory st\u00e1le zaj\u00edmav\u011bj\u0161\u00ed. Hodnota v tomto segmentu nevznik\u00e1 jen v samotn\u00e9m produktu, ale p\u0159edev\u0161\u00edm v kombinaci du\u0161evn\u00edho vlastnictv\u00ed, certifikace, klinick\u00e9 validace, regulatorn\u00ed p\u0159ipravenosti a schopnosti \u0161k\u00e1lovat \u0159e\u0161en\u00ed nap\u0159\u00ed\u010d trhy.<\/p>\n\n\n\n
Pr\u00e1v\u011b v t\u00e9to logice je pot\u0159eba vn\u00edmat i dal\u0161\u00ed krok H2 Global Group. Skupina toti\u017e nen\u00ed pouze investorem do perspektivn\u00edch projekt\u016f, ale sou\u010dasn\u011b rozv\u00edj\u00ed i vlastn\u00ed technologickou a patentovou z\u00e1kladnu prost\u0159ednictv\u00edm sv\u00e9 dce\u0159in\u00e9 spole\u010dnosti H2 Medical Technologies. Sou\u010d\u00e1st\u00ed spole\u010dn\u00e9ho inova\u010dn\u00edho r\u00e1mce H2 Medical Technologies a projektu VR Vitalis je tak\u00e9 unik\u00e1tn\u00ed patentov\u011b p\u0159ipravovan\u00e9 \u0159e\u0161en\u00ed, kter\u00e9 propojuje molekul\u00e1rn\u00ed vod\u00edk s virtu\u00e1ln\u00ed realitou pro rehabilitaci plic. Na tuto technologickou kombinaci ji\u017e byl zpracov\u00e1n u\u017eitn\u00fd vzor a pod\u00e1na patentov\u00e1 p\u0159ihl\u00e1\u0161ka. Tento krok potvrzuje, \u017ee ambic\u00ed skupiny nen\u00ed pouze rozv\u00edjet jednotliv\u00e9 produkty, ale budovat \u0161ir\u0161\u00ed platformu chr\u00e1n\u011bnou du\u0161evn\u00edm vlastnictv\u00edm s potenci\u00e1lem dal\u0161\u00ed klinick\u00e9 validace i komer\u010dn\u00edho vyu\u017eit\u00ed.<\/p>\n\n\n\n
H2 Global Group na v\u00edce ne\u017e 19 letech v\u00fdzkumu a v\u00fdvoje, op\u00edr\u00e1 se o evropsk\u00fd patent EP 3701956 a v lednu 2026 po schv\u00e1len\u00ed St\u00e1tn\u00edm \u00fastavem pro kontrolu l\u00e9\u010div (S\u00daKL) prost\u0159ednictv\u00edm sv\u00e9 dce\u0159in\u00e9 spole\u010dnosti H2 Medical Technologies zah\u00e1jila klinickou studii a sou\u010dasn\u011b vstoupila do registra\u010dn\u00ed f\u00e1ze prvn\u00edho zdravotnick\u00e9ho prost\u0159edku na sv\u011bt\u011b vyu\u017e\u00edvaj\u00edc\u00edho molekul\u00e1rn\u00ed vod\u00edk. P\u0159i sou\u010dasn\u00e9 pre-money valuaci 1,6 miliardy K\u010d pracuje spole\u010dnost s ambic\u00ed st\u00e1t se b\u011bhem t\u0159\u00ed let akvizi\u010dn\u00edm c\u00edlem pro siln\u00e9ho mezin\u00e1rodn\u00edho strategick\u00e9ho partnera, s potenci\u00e1ln\u00ed transakc\u00ed v rozmez\u00ed 0,5 a\u017e 1,5 miliardy USD, tedy p\u0159ibli\u017en\u011b 11,5 a\u017e 34,5 miliardy K\u010d. Jin\u00fdmi slovy: firma m\u00ed\u0159\u00ed na hodnotu odpov\u00eddaj\u00edc\u00ed p\u0159ibli\u017en\u011b 7 a\u017e 22n\u00e1sobku dne\u0161n\u00ed valuace.<\/p>\n\n\n\n
Potenci\u00e1l t\u00e9to oblasti nav\u00edc podporuje v\u00edce ne\u017e 3 000 v\u011bdeck\u00fdch publikac\u00ed zam\u011b\u0159en\u00fdch na vyu\u017eit\u00ed molekul\u00e1rn\u00edho vod\u00edku v medic\u00edn\u011b, v\u010detn\u011b v\u00edce ne\u017e 150 studi\u00ed na lidech, co\u017e z H2 Global Group d\u011bl\u00e1 projekt s parametry, kter\u00e9 investo\u0159i v medic\u00ednsk\u00fdch technologi\u00edch (MedTech) sleduj\u00ed velmi pozorn\u011b. Z pohledu trhu tak nejde jen o dal\u0161\u00ed startupov\u00fd p\u0159\u00edb\u011bh, ale o spole\u010dnost, kter\u00e1 propojuje patentov\u011b chr\u00e1n\u011bnou technologii, klinick\u00fd posun, regulatorn\u00ed postup a investi\u010dn\u00ed r\u016fstov\u00fd potenci\u00e1l.<\/p>\n\n\n\n
\u201eDlouhodob\u011b velmi citliv\u011b vn\u00edm\u00e1m, v jak\u00e9m stavu se dnes zdravotnictv\u00ed nach\u00e1z\u00ed, zejm\u00e9na pokud jde o du\u0161evn\u00ed zdrav\u00ed d\u011bt\u00ed, kvalitu \u017eivota senior\u016f i lid\u00ed, kte\u0159\u00ed do vy\u0161\u0161\u00edho v\u011bku teprve postupn\u011b vstupuj\u00ed. To jsou jedny z nejv\u011bt\u0161\u00edch spole\u010densk\u00fdch v\u00fdzev sou\u010dasnosti a u\u017e nen\u00ed mo\u017en\u00e9 je d\u00e1l p\u0159ehl\u00ed\u017eet. Jsem p\u0159esv\u011bd\u010den, \u017ee spole\u010dn\u011b s na\u0161\u00edm mezin\u00e1rodn\u00edm t\u00fdmem, kter\u00fd propojuje \u0161pi\u010dkov\u00e9 japonsk\u00e9 v\u011bdce a l\u00e9ka\u0159e s \u010desk\u00fdmi odborn\u00edky, inov\u00e1tory a dal\u0161\u00edmi experty ze zahrani\u010d\u00ed, dok\u00e1\u017eeme nab\u00eddnout sv\u011btu udr\u017eiteln\u00e1, neinvazivn\u00ed a funk\u010dn\u00ed \u0159e\u0161en\u00ed s re\u00e1ln\u00fdm dopadem na kvalitu \u017eivota lid\u00ed. Na\u0161\u00ed ambic\u00ed toti\u017e nen\u00ed jen vyv\u00edjet nov\u00e9 technologie, ale prom\u011b\u0148ovat je v dostupn\u00e9 inovace s dlouhodob\u00fdm p\u0159\u00ednosem pro celou spole\u010dnost. Tento p\u0159\u00edstup zt\u011bles\u0148uje i na\u0161e neinvazivn\u00ed vod\u00edkov\u00e9 \u0159e\u0161en\u00ed, kter\u00e9 m\u00e1 budouc\u00ed uplatn\u011bn\u00ed nejen v oblasti prevence a podpory l\u00e9\u010dby Alzheimerovy demence a m\u00edrn\u00e9 kognitivn\u00ed poruchy (MCI), ale tak\u00e9 u \u0161irok\u00e9ho spektra z\u00e1n\u011btliv\u00fdch proces\u016f v organismu. Pr\u00e1v\u011b v t\u011bchto oblastech dnes medic\u00edna hled\u00e1 nov\u00e9, bezpe\u010dn\u00e9 a funk\u010dn\u00ed cesty, jak pacient\u016fm nab\u00eddnout vy\u0161\u0161\u00ed kvalitu \u017eivota, \u00fa\u010dinn\u011bj\u0161\u00ed dlouhodobou podporu a ve v\u00fdsledku i lep\u0161\u00ed a zdrav\u011bj\u0161\u00ed spole\u010dnost,\u201c \u0159\u00edk\u00e1 David Mar\u0161\u00e1lek, gener\u00e1ln\u00ed \u0159editel a zakladatel H2 Global Group.<\/p>\n\n\n\n
P\u0159\u00edb\u011bh VR LIFE a produktu VR Vitalis tak nen\u00ed jen \u00fasp\u011bchem jedn\u00e9 firmy. Pro H2 Global Group p\u0159edstavuje konkr\u00e9tn\u00ed d\u016fkaz, \u017ee dob\u0159e na\u010dasovan\u00e1 investice do \u010desk\u00e9ho MedTechu m\u016f\u017ee p\u0159in\u00e1\u0161et nejen strategick\u00fd v\u00fdznam, ale i rychle rostouc\u00ed hodnotu. A pr\u00e1v\u011b to je pro investory jeden z nejd\u016fle\u017eit\u011bj\u0161\u00edch sign\u00e1l\u016f. \u010cesk\u00fd MedTech dnes ukazuje, \u017ee i na dom\u00e1c\u00edm trhu mohou vznikat projekty s klinick\u00fdm, mezin\u00e1rodn\u00edm i investi\u010dn\u00edm potenci\u00e1lem. H2 Global Group pat\u0159\u00ed mezi spole\u010dnosti, kter\u00e9 tento trend dok\u00e1\u017eou nejen rozpoznat, ale tak\u00e9 aktivn\u011b spoluvytv\u00e1\u0159et.\n\n\n\n\n\nZdroj: https:\/\/www.penize.cz\/tiskove-zpravy\/487602-silny-signal-pro-investory-vr-life-a-h2-global-group-potvrzuji-hodnotu-ceskych-inovaci-v-medtechu<\/p>\n\n\n\n\n\n
<\/p>\n\n\n\n\n\n\n\n\n\n\n\n
<\/p>\n\n\n\n\n\n
<\/p>","protected":false},"excerpt":{"rendered":"
A Strong Signal for Investors: VR LIFE and H2 Global Group Confirm the Value of Czech Innovations in MedTech Czech MedTech is no longer a fringe topic and is beginning to establish itself as a sector capable of combining technological innovation, clinical utility, and attractive value growth. It is precisely in this environment that H2… Siln\u00fd sign\u00e1l pro investory: VR LIFE a H2 Global Group potvrzuj\u00ed hodnotu \u010desk\u00fdch inovac\u00ed v MedTechu<\/span><\/a><\/p>","protected":false},"author":1,"featured_media":1228,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"neve_meta_sidebar":"","neve_meta_container":"","neve_meta_enable_content_width":"","neve_meta_content_width":0,"neve_meta_title_alignment":"","neve_meta_author_avatar":"","neve_post_elements_order":"","neve_meta_disable_header":"","neve_meta_disable_footer":"","neve_meta_disable_title":"","_themeisle_gutenberg_block_has_review":false,"footnotes":""},"categories":[1],"tags":[],"class_list":["post-1227","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-uncategorized"],"_links":{"self":[{"href":"https:\/\/www.h2founders.com\/cs\/wp-json\/wp\/v2\/posts\/1227","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.h2founders.com\/cs\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.h2founders.com\/cs\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.h2founders.com\/cs\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.h2founders.com\/cs\/wp-json\/wp\/v2\/comments?post=1227"}],"version-history":[{"count":4,"href":"https:\/\/www.h2founders.com\/cs\/wp-json\/wp\/v2\/posts\/1227\/revisions"}],"predecessor-version":[{"id":1233,"href":"https:\/\/www.h2founders.com\/cs\/wp-json\/wp\/v2\/posts\/1227\/revisions\/1233"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.h2founders.com\/cs\/wp-json\/wp\/v2\/media\/1228"}],"wp:attachment":[{"href":"https:\/\/www.h2founders.com\/cs\/wp-json\/wp\/v2\/media?parent=1227"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.h2founders.com\/cs\/wp-json\/wp\/v2\/categories?post=1227"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.h2founders.com\/cs\/wp-json\/wp\/v2\/tags?post=1227"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}